ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumors

ONO-7914-01:A Phase I, open-label, uncontrolled, dose escalation study to evaluate the tolerability and safety of ONO-7914 alone and in combination with ONO-4538 in patients with advanced or metastatic solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210530

Enrollment

204

Registered

2021-12-28

Start date

2022-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or metastatic solid tumors

Interventions

ONO-7914 is administered as a single agent or combination with ONO-4538.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with advanced or metastatic solid tumor 2.Patients with ECOG performance status of 0 or 1 3.Patients with a life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: 1.Patients with severe complication 2.Patients judged to be incapable of providing consent for reasons such as concurrent dementia

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Secondary

Measure	Time frame
Pharmacokinetics for ONO-7914 and ONO-4538	—

Contacts

Public ContactSupport Desk JP

Ono Pharmaceutical Co.,LTD

clinical_trial@ono.co.jp+81-120-278-120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026